[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.", "fullTimeEmployees": 227, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 64, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 62, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 1009003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 62, "title": "Chief Technical Advisor", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 734607, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 50, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}, {"maxAge": 1, "name": "Mr. Kristian  Humer M.B.A.", "age": 50, "title": "CFO & Principal Financial Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ashoo  Gupta", "age": 49, "title": "Principal Accounting Officer & Principal Financial Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Julian  Pei", "title": "Head of Investor Relations & Corporate Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Katy  Barglow Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott P. Bizily J.D., Ph.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Translational Medicine Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.36, "open": 9.39, "dayLow": 9.28, "dayHigh": 9.78, "regularMarketPreviousClose": 9.36, "regularMarketOpen": 9.39, "regularMarketDayLow": 9.28, "regularMarketDayHigh": 9.78, "payoutRatio": 0.0, "beta": 3.009, "forwardPE": -2.6879866, "volume": 679044, "regularMarketVolume": 679044, "averageVolume": 905290, "averageVolume10days": 796820, "averageDailyVolume10Day": 796820, "bid": 9.32, "ask": 9.38, "bidSize": 1, "askSize": 1, "marketCap": 534212992, "fiftyTwoWeekLow": 2.235, "fiftyTwoWeekHigh": 12.34, "allTimeHigh": 55.11, "allTimeLow": 2.235, "priceToSalesTrailing12Months": 4451.775, "fiftyDayAverage": 8.828, "twoHundredDayAverage": 7.164575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 251412944, "profitMargins": 0.0, "floatShares": 41202388, "sharesOutstanding": 51007874, "sharesShort": 9282692, "sharesShortPriorMonth": 8677770, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.18200001, "heldPercentInsiders": 0.03615, "heldPercentInstitutions": 0.87285006, "shortRatio": 12.02, "shortPercentOfFloat": 0.18879999, "impliedSharesOutstanding": 57135075, "bookValue": 7.889, "priceToBook": 1.1851946, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -209176992, "trailingEps": -3.75, "forwardEps": -3.47844, "enterpriseToRevenue": 2095.108, "enterpriseToEbitda": -1.129, "52WeekChange": 0.92989695, "SandP52WeekChange": 0.11471915, "quoteType": "EQUITY", "currentPrice": 9.35, "targetHighPrice": 45.0, "targetLowPrice": 17.0, "targetMeanPrice": 33.11111, "targetMedianPrice": 33.0, "recommendationKey": "none", "numberOfAnalystOpinions": 9, "totalCash": 305063008, "totalCashPerShare": 5.339, "ebitda": -222704992, "totalDebt": 22263000, "quickRatio": 8.221, "currentRatio": 8.418, "totalRevenue": 120000, "debtToEquity": 6.034, "revenuePerShare": 0.002, "returnOnAssets": -0.27636, "returnOnEquity": -0.45378, "grossProfits": -177955008, "freeCashflow": -103545376, "operatingCashflow": -183496000, "revenueGrowth": 29.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -655.3889, "financialCurrency": "USD", "symbol": "FDMT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "regularMarketChangePercent": -0.10683, "regularMarketPrice": 9.35, "corporateActions": [], "marketState": "CLOSED", "earningsTimestampStart": 1762781400, "earningsTimestampEnd": 1762781400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.75, "epsForward": -3.47844, "epsCurrentYear": -3.2586, "priceEpsCurrentYear": -2.8693304, "fiftyDayAverageChange": 0.5220003, "fiftyDayAverageChangePercent": 0.059130076, "twoHundredDayAverageChange": 2.1854253, "twoHundredDayAverageChangePercent": 0.30503207, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-12-11", "cryptoTradeable": false, "postMarketTime": 1771030167, "regularMarketTime": 1771016402, "exchange": "NMS", "messageBoardId": "finmb_272879653", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1607697000000, "postMarketChangePercent": 0.5347512, "postMarketPrice": 9.4, "postMarketChange": 0.049999237, "regularMarketChange": -0.00999928, "regularMarketDayRange": "9.28 - 9.78", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 905290, "fiftyTwoWeekLowChange": 7.1150007, "fiftyTwoWeekLowChangePercent": 3.1834457, "fiftyTwoWeekRange": "2.235 - 12.34", "fiftyTwoWeekHighChange": -2.9899998, "fiftyTwoWeekHighChangePercent": -0.24230143, "fiftyTwoWeekChangePercent": 92.98969, "displayName": "4D Molecular Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-14"}]